Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at CHOP-R and Zevalin for patients over 60 years old with diffuse large B cell non Hodgkin lymphoma
This trial was looking at a short course of chemotherapy with a new drug called Zevalin for people over 60 years of age with diffuse large B cell non Hodgkin lymphoma.
Diffuse large B cell non Hodgkin lymphoma is a type of high grade (aggressive) non Hodgkin lymphoma (NHL). When this trials started, the standard treatment for all B cell lymphomas was a combination of drugs called CHOP-R. This includes the chemotherapy drugs cyclophosphamide, doxorubicin (Adriamycin), vincristine, the steroid prednisolone and a monoclonal antibody called rituximab (Mabthera). Some patients over 60 years old are not well enough to have 6 cycles of full dose CHOP-R treatment. Doctors though that having less CHOP-R and adding a new drug called Y ibritumomab tiuxetan (Zevalin) might be better for this group of patients.
Zevalin is a radio labelled monoclonal antibody. This means it has a radioactive molecule called yttrium 90 attached to it. The antibody targets the CD20 protein on the surface of NHL B cells, and the radioactive yttrium kills them. Previous trials on a small number of patients with aggressive lymphoma had shown that a single dose of Zevalin could work well and improve quality of life.
The aims of the trial were to find out
- The best dose of Zevalin to use
- What the side effects are
- How well it works for diffuse large B cell NHL
Summary of results
We have contacted the trial team who tell us they were unable to recruit enough patients and don’t expect to be publishing results for this trial.
How to join a clinical trial
Professor Tim Illidge
Experimental Cancer Medicine Centre (ECMC)
The Christie NHS Foundation Trust